Pubblicazioni Scientifiche

Ricerca su tutti i campi

Ricerca avanzata

Tipo pubbl.	Pubblicazione
Conference Abstract	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib J Clin Oncol 2019;37( ): - .
Journal Article	Sclerodermic hand: Subclinical joint involvement? Ann Rheum Dis 2019;78( ):1801- .
Conference Abstract	Nelarabine as salvage therapy and bridge to allogeneic stem cells transplantation in 118 adult patients with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. A campus-all, phase 4, study Haematologica 2019;104( ):92-93.
Conference Abstract	Outcome of allogeneic-HSCT in 441 adult patients with ph-positive-all in the era of TKI: A retrospective analysis of the Italian blood and marrow transplantation society (GITMO) Haematologica 2019;104( ):21- .
Conference Abstract	From hero to (almost) zero: The hidden dangers of whole-exome sequencing in disease-gene discovery Eur J Hum Genet 2019;26( ):187- .
Conference Abstract	Renal safety in 3, 264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study J Hepatol 2019;70(1):e215-e216.
Conference Abstract	Diabetes is associated with TIPS failure in cirrhotic patients with refractory ascites J Hepatol 2019;70(1):e636-e637.
Conference Abstract	Major responses in MYD88 wildtype (MYD88WT) waldenstrom macroglobulinemia (WM) patients treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) HemaSphere 2019;3( ):196- .
Conference Abstract	An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 or more prior therapies Hematol Oncol 2019;37( ):213-214.
Conference Abstract	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial J Clin Oncol 2019;37( ): - .
Conference Abstract	Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial Clin Lymphoma Myeloma Leukemia 2019;19( ):S273-S274.
Conference Abstract	Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients Dig Liver Dis 2019;51( ):e55-e56.
Conference Abstract	Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients J Hepatol 2019;70(1):e223-e224.
Conference Abstract	A whole-genome epigenomic approach in multiple sclerosis multiplex families revealed new epigenetic traits involved in the disease Eur J Neurol 2019;26( ):243- .
Conference Abstract	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory CLL/SLL in the duo trial Hematol Oncol 2019;37( ):214-216.
Conference Abstract	Efficacy of BCL2 inhibitor in CLL patients who progressed after B-cell receptor inhibitors: A retrospective multicenter Italian experience Haematologica 2019;104( ):104-105.
Conference Abstract	In adult Acute Myeloid Leukemia (AML) peripheral blood Measurable Residual Disease (MRD) by flow cytometry (FC) is feasible and is prognostically relevant Haematologica 2019;104( ):12-13.
Conference Abstract	Comparative clinical effectiveness of azacitidine versus decitabine for the front line treatment of elderly acute myeloid leukemia (AML) patients Haematologica 2019;104( ):89- .
Conference Abstract	Severe infections and pneumonia in patients with chronic lymphocytic leukemia (CLL) treated with Kinase inhibitors (KIS) ibrutinib or idelalisib in the real world Haematologica 2019;104( ):100- .
Conference Abstract	Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy Dig Liver Dis 2019;51( ):e16-e17.

Risultati da 1 a 20 di 7060 totali

- Successiva

AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA | Piazza Ospedale Maggiore 3 | 20162 Milano | t. +39 02 6444.1 - f. +39 02 6420901 | CF e Partita IVA: 11390840152